Accelerating China Origin Innovation into Global Markets with End-to-End Clinical Drug Development Support

Chinese biotech companies are transforming drug discovery with groundbreaking Chinese innovations, while US biotech companies and global pharmaceutical organizations are increasingly licensing Chinese drugs to strengthen their development pipelines. From innovative oncology therapies to biologics and rare disease treatments, Chinese cancer drugs and other novel therapies are transforming global drug development.

Successfully advancing these licensed assets demands an experienced partner capable of managing every stage of clinical development. Whether your organization has licensed an early-stage molecule, is preparing an IND or is advancing a Phase III program toward commercialization, Navitas Life Sciences provides integrated, end-to-end support that accelerates development while reducing operational complexity and regulatory risk.

Our multidisciplinary teams bring together experts in Clinical Operations, Clinical Data Sciences, Regulatory Affairs, Medical Writing, Pharmacovigilance, Bioanalytical Services and Project Management to deliver seamless global execution. We understand the complexities of cross-border development, stringent USFDA guidance, data quality expectations, data integrity guideline USFDA requirements and collaboration across global stakeholders.

Our cross border clinical drug development services are extensive and include:

Supporting Licensed Assets from China Across Every Development Stage

Early-Stage Development

Comprehensive support for asset evaluation, regulatory gap analysis, clinical development planning, IND strategy, medical writing and early clinical studies.

Mid-Stage Development

Integrated clinical operations, data sciences, pharmacovigilance, medical monitoring, regulatory support and global project management for Phase I and Phase II programs.

Late-Stage Development

Global Phase III execution, regulatory submissions, safety surveillance, clinical data management, medical writing and commercialization readiness.

Lifecycle Management

Post-marketing surveillance, regulatory maintenance, labeling support, real-world evidence and ongoing safety monitoring.

Brochure

Efficient Clinical Trials: Real-Time Oversight & Insights

Navitas Life Sciences has In-depth domain expertise, vast experience in managing global studies, incorporated proven technologies, and more to manage efficient trials.

CASE STUDY

Successful First-In-Human Phase-I Study in Advanced Solid Malignancies

In this cancer case study, learn how we ensured 100% Successful Complex First-In-Human (FIH) Phase-I multicentre, open-label, dose-escalation study in adult patients with advanced solid malignancies.